US Patent Issued to Tempus AI on Sept. 9 for "Methods for evaluating the effect of the start date for cancer treatment with a cancer medication using propensity scoring" (Illinois, Washington Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,412,665, issued on Sept. 9, was assigned to Tempus AI Inc. (Chicago).

"Methods for evaluating the effect of the start date for cancer treatment with a cancer medication using propensity scoring" was invented by Ashraf Hafez (Woodinville, Wash.) and Caroline Epstein (Chicago).

According to the abstract* released by the U.S. Patent & Trademark Office: "An evaluation of a cancer treatment start date for a cancer medication identifies a first plurality of subjects and, for each, the treatment start date. A subject is selected for a second plurality of subjects by applying features for the subject to a model at a propensity value threshold. One subset of the features is associated with a...